The FDA has approved regorafenib (Stivarga) for the second-line treatment of hepatocellular carcinoma (HCC) for patients who have previously received sorafenib.
The FDA on March 23, 2017, granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.
The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.
The FDA granted accelerated approval to rucaparib (Rubraca), a PARP inhibitor, for the treatment of women with deleterious BRCA mutation-associated ovarian cancer.
The addition of selumetinib to docetaxel failed to improve progression-free and overall survival in patients with KRAS-mutated locally advanced or metastatic NSCLC.
The use of the PD1 inhibitor nivolumab appeared to be feasible and safe in a small study of patients with untreated, stage I–IIIa non–small-cell lung cancer.
Adding ribociclib, a CDK4/6 inhibitor, to letrozole significantly improved progression-free survival in postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.
Genmab recently announced that the US Food and Drug Administration has approved ofatumumab (Arzerra®) combined with fludarabine and cyclophosphamide (FC) for patients with relapsed chronic lymphocytic leukemia.
Treatment with the anti–PD-1 antibody pembrolizumab was safe and active in a small study of patients with relapsed or refractory classical Hodgkin lymphoma whose disease progressed after treatment with brentuximab vedotin.